Insider Buying: Vivani Medical (NASDAQ:VANI) Director Purchases $47,619.00 in Stock

Key Points

  • Vivani Medical Director Gregg Williams bought 48,100 shares at an average price of $0.99, spending $47,619. The purchase increased his position by 0.13%, to 36,960,836 shares.
  • Vivani reported a quarterly loss of $0.08 per share, slightly better than analysts’ expected loss of $0.09.
  • Analyst sentiment is mixed: MarketBeat’s consensus rating is Hold, with a $3.75 price target; the stock opened at $1.02 and has traded between $0.80 and $1.66 over the past year.

Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams purchased 48,100 shares of the firm's stock in a transaction on Friday, November 13th. The stock was acquired at an average cost of $0.99 per share, for a total transaction of $47,619.00. Following the completion of the purchase, the director owned 36,960,836 shares in the company, valued at $36,591,227.64. The trade was a 0.13% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Vivani Medical Trading Up 1.0%

Shares of Vivani Medical stock opened at $1.02 on Tuesday. The business's fifty day moving average price is $1.17 and its 200 day moving average price is $1.24. Vivani Medical, Inc. has a twelve month low of $0.80 and a twelve month high of $1.66. The stock has a market capitalization of $92.00 million, a P/E ratio of -3.19 and a beta of 2.51.

Vivani Medical (NASDAQ:VANI - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01.

Wall Street Analysts Forecast Growth




A number of research analysts have recently issued reports on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Vivani Medical in a research report on Friday, October 2nd. Wall Street Zen downgraded Vivani Medical from a "hold" rating to a "sell" rating in a research note on Sunday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Vivani Medical has a consensus rating of "Hold" and a consensus price target of $3.75.

Read Our Latest Stock Report on VANI

Vivani Medical Company Profile

(Get Free Report)

Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.

Recommended Stories

Insider Buying and Selling by Quarter for Vivani Medical (NASDAQ:VANI)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Vivani Medical?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Vivani Medical and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles